SynBiotic SE
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. T… Read more
SynBiotic SE (SBX) - Net Assets
Latest net assets as of December 2022: €22.79 Million EUR
Based on the latest financial reports, SynBiotic SE (SBX) has net assets worth €22.79 Million EUR as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€40.62 Million) and total liabilities (€17.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €22.79 Million |
| % of Total Assets | 56.1% |
| Annual Growth Rate | 183.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4643.84 |
SynBiotic SE - Net Assets Trend (2019–2023)
This chart illustrates how SynBiotic SE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SynBiotic SE (2019–2023)
The table below shows the annual net assets of SynBiotic SE from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €15.33 Million | -32.74% |
| 2022-12-31 | €22.79 Million | -37.94% |
| 2021-12-31 | €36.72 Million | +44.04% |
| 2020-12-31 | €25.50 Million | +10715.33% |
| 2019-12-31 | €235.75K | -- |
Equity Component Analysis
This analysis shows how different components contribute to SynBiotic SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4860008500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €64.40 Million | 407.88% |
| Total Equity | €15.79 Million | 100.00% |
SynBiotic SE Competitors by Market Cap
The table below lists competitors of SynBiotic SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AJWA for Food Industries company Egypt
EGX:AJWA
|
$21.94K |
|
FIRSTGROUP
BE:FGR
|
$21.95K |
|
LI NING
MU:LNLB
|
$21.96K |
|
EO2 SA
BE:EO4
|
$21.96K |
|
AS-IP Tech Inc
PINK:IPTK
|
$21.94K |
|
Doric Nimrod Air Two Limited
LSE:DNA2
|
$21.92K |
|
Misr Conditioning (Miraco)
EGX:MRCO
|
$21.92K |
|
EALT3F
SA:EALT3F
|
$21.87K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SynBiotic SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 22,593,075 to 15,789,870, a change of -6,803,205 (-30.1%).
- Net loss of 10,630,597 reduced equity.
- New share issuances of 3,156,893 increased equity.
- Other factors increased equity by 670,499.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.63 Million | -67.33% |
| Share Issuances | €3.16 Million | +19.99% |
| Other Changes | €670.50K | +4.25% |
| Total Change | €- | -30.11% |
Book Value vs Market Value Analysis
This analysis compares SynBiotic SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.70x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.34x to 0.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.94 | €2.21 | x |
| 2020-12-31 | €9.67 | €2.21 | x |
| 2021-12-31 | €9.53 | €2.21 | x |
| 2022-12-31 | €5.00 | €2.21 | x |
| 2023-12-31 | €3.15 | €2.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SynBiotic SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -275.31%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 2.21x
- Recent ROE (-67.33%) is below the historical average (-43.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -5.70% | 0.00% | 0.00x | 1.01x | €-37.00K |
| 2020 | -2.47% | -567.57% | 0.00x | 1.37x | €-3.18 Million |
| 2021 | -36.36% | -140.39% | 0.15x | 1.73x | €-16.22 Million |
| 2022 | -107.83% | -298.35% | 0.20x | 1.80x | €-26.62 Million |
| 2023 | -67.33% | -275.31% | 0.11x | 2.21x | €-12.21 Million |
Industry Comparison
This section compares SynBiotic SE's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SynBiotic SE (SBX) | €22.79 Million | -5.70% | 0.78x | $21.94K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $243.78K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.26K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $987.66 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $77.40 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.57 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.73 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |